This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Columbia considers costs for omalizumab. Pharmacoecon. Outcomes News 656, 8 (2012). https://doi.org/10.2165/00151234-201206560-00010
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201206560-00010